Establishment of Nose-to-Brain Delivery Strategy for Treatment of Dementia Based on Pharmacokinetic and Therapeutic Analyses

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07032
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47020:Pharmaceutical analytical chemistry and physicochemistry-related
• Research Institution: Kobe Gakuin University
• Principal Investigator: Kamei Noriyasu 神戸学院大学, 薬学部, 講師 (40637451)
• Co-Investigator(Kenkyū-buntansha): 武田 真莉子 神戸学院大学, 薬学部, 教授 (70257096)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 経鼻投与 / 脳内デリバリー / ペプチド薬物 / 抗体薬 / 細胞膜透過ペプチド / アルツハイマー病 / 認知症

Outline of Final Research Achievements

In this study, we aimed to clarify the involvement of direct nose-to-brain transport pathways in the enhanced brain delivery via the intranasal coadministration strategy with cell-penetrating peptides (CPPs). Moreover, we investigated the applicability of our strategy to the delivery of anti-amyloid beta antibody to the brain and improvement of the therapeutic potential of the drugs in amyloid precursor protein (APP) knock-in mice. Through this study, we tried to demonstrate the usefulness of nose-to-brain delivery via intranasal administration with CPPs for treating dementia.

Free Research Field

薬剤学

Academic Significance and Societal Importance of the Research Achievements

本研究を通じて、CPP併用経鼻投与法が高分子量バイオ医薬品の送達効率を飛躍的に向上させる有用な戦略となりうることを実証した。本投与戦略を認知症治療薬の開発研究に導入することにより、認知症治療薬としての実用化が停滞する疾患修飾薬の開発を促進できる可能性が示唆された。